撒哈拉以南非洲口服霍乱疫苗地理靶向接种的模型预测影响
该建模研究比较了2018至2030年撒哈拉以南非洲按不同地理策略接种口服霍乱疫苗的影响。按历史负担优化策略预计可避免828,971例病例(占预测病例34.0%),平衡物流可行性与历史负担策略可避免617,424例。地理靶向能显著提升成本效果,但仅靠疫苗难以实现2030年全球霍乱死亡减少90%的目标。
要点
- 按历史霍乱负担地理靶向接种可避免828,971例病例,占预测病例34.0%。
- 最物流可行的靶向策略每避免一个DALY成本为1,843美元。
- 仅靠疫苗不辅以水和卫生设施改善或供应大增,难以达成2030目标。
核心结论
- 地理靶向可大幅提升口服霍乱疫苗接种的成本效果和影响。
- 历史霍乱负担最高地区与改良水和卫生设施可及性最差地区并不重合。
- 仅靠疫苗使用不太可能实现2030年全球霍乱死亡减少90%的目标。
研究设计与样本
- 建模研究,比较2018至2030年撒哈拉以南非洲不同地理靶向接种策略的预测影响。
- 模型考虑疫苗直接和间接效应及人口预测,评估避免病例、死亡、DALY和成本效果。
主要发现
- 按历史负担优化策略预计避免828,971例(95%CI 803,370-859,980),占预测病例34.0%(95%CI 33.2%-34.8%)。
- 平衡物流可行性与历史负担策略预计避免617,424例(95%CI 599,150-643,891)。
- 按水和卫生设施可及性有限地区优化策略分别避免273,939例(95%CI 270,319-277,002)和109,817例(95%CI 103,735-114,110)。
关键数值与推荐
- 最物流可行的靶向策略每避免一个DALY成本为1,843美元(95%CI 1,328-14,312)。
- 有效地理靶向对成本效果的影响可大于疫苗效力提升和覆盖率中度增加。
临床怎么用
- 规划霍乱控制时应优先按历史负担进行地理靶向以最大化疫苗影响和成本效果。
- 不应仅以水和卫生设施可及性最差地区替代历史霍乱高负担地区作为接种靶向依据。
局限性
- 模型未预测基线霍乱风险的年度变化。
- 模型未直接纳入自然霍乱感染获得的免疫力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cholera causes an estimated 100,000 deaths annually worldwide, with the majority of burden reported in sub-Saharan Africa. In May 2018, the World Health Assembly committed to reducing worldwide cholera deaths by 90% by 2030. Oral cholera vaccine (OCV) plays a key role in reducing the near-term risk of cholera, although global supplies are limited. Characterizing the potential impact and cost-effectiveness of mass OCV deployment strategies is critical for setting expectations and developing cholera control plans that maximize the chances of success. METHODS AND FINDINGS: We compared the projected impacts of vaccination campaigns across sub-Saharan Africa from 2018 through 2030 when targeting geographically according to historical cholera burden and risk factors. We assessed the number of averted cases, deaths, and disability-adjusted life years and the cost-effectiveness of these campaigns with models that accounted for direct and indirect vaccine effects and population projections over time. Under current vaccine supply projections, an approach optimized to targeting by historical burden is projected to avert 828,971 (95% CI 803,370-859,980) cases (equivalent to 34.0% of projected cases; 95% CI 33.2%-34.8%). An approach that balances logistical feasibility with targeting historical burden is projected to avert 617,424 (95% CI 599,150-643,891) cases. In contrast, approaches optimized for targeting locations with limited access to water and sanitation are projected to avert 273,939 (95% CI 270,319-277,002) and 109,817 (95% CI 103,735-114,110) cases, respectively. We find that the most logistically feasible targeting strategy costs US$1,843 (95% CI 1,328-14,312) per DALY averted during this period and that effective geographic targeting of OCV campaigns can have a greater impact on cost-effectiveness than improvements to vaccine efficacy and moderate increases in coverage. Although our modeling approach does not project annual changes in baseline cholera risk or directly incorporate immunity from natural cholera infection, our estimates of the relative performance of different vaccination strategies should be robust to these factors. CONCLUSIONS: Our study suggests that geographic targeting substantially improves the cost-effectiveness and impact of oral cholera vaccination campaigns. Districts with the poorest access to improved water and sanitation are not the same as districts with the greatest historical cholera incidence. While OCV campaigns can improve cholera control in the near term, without rapid progress in developing water and sanitation services or dramatic increases in OCV supply, our results suggest that vaccine use alone is unlikely to allow us to achieve the 2030 goal.
引用
- Lee EC, Azman AS, Kaminsky J, et al. The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study. PLoS Med. 2019. PMID: 31825965. doi:10.1371/journal.pmed.1003003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。